Key Points
- Insider sale: Mike Mensinger sold 2,200 BBNX shares on Jan 6 at $30.10 for $66,220 and has made additional recent sales (7,800 on Jan 2 and 1,063 on Dec 2), reducing his direct stake to 80,752 shares (a 2.65% decrease) valued at about $2.43M.
- Company and stock snapshot: Beta Bionics has a market cap of ~$1.39 billion, is trading near its 12‑month high (~$31), has a negative P/E, and recently reported ($0.33) EPS with $27.25M in revenue, beating estimates despite negative margins.
- Institutional and analyst interest: Major institutions like Vanguard have materially increased positions (Vanguard now owns ~2.22M shares), and analysts collectively give a "Moderate Buy" consensus with a $29.70 target while several firms have raised targets into the low‑$30s.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mike Mensinger sold 2,200 shares of Beta Bionics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $30.10, for a total value of $66,220.00. Following the sale, the insider directly owned 80,752 shares in the company, valued at approximately $2,430,635.20. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Mike Mensinger also recently made the following trade(s):
- On Friday, January 2nd, Mike Mensinger sold 7,800 shares of Beta Bionics stock. The shares were sold at an average price of $29.61, for a total value of $230,958.00.
- On Tuesday, December 2nd, Mike Mensinger sold 1,063 shares of Beta Bionics stock. The shares were sold at an average price of $29.34, for a total value of $31,188.42.
Beta Bionics Trading Up 0.3%
BBNX stock opened at $31.49 on Thursday. The firm has a 50 day simple moving average of $29.32 and a 200-day simple moving average of $22.17. The company has a market capitalization of $1.39 billion and a P/E ratio of -7.21. Beta Bionics, Inc. has a twelve month low of $8.89 and a twelve month high of $32.71.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.12. The firm had revenue of $27.25 million for the quarter, compared to the consensus estimate of $23.92 million. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%.
Institutional Trading of Beta Bionics
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company's stock worth $44,036,000 after purchasing an additional 1,509,217 shares during the last quarter. Divisadero Street Capital Management LP acquired a new stake in Beta Bionics in the 2nd quarter valued at approximately $13,817,000. Sands Capital Alternatives LLC increased its position in Beta Bionics by 15.0% in the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company's stock valued at $51,981,000 after acquiring an additional 466,331 shares during the period. Soleus Capital Management L.P. raised its stake in Beta Bionics by 12.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company's stock valued at $55,622,000 after acquiring an additional 424,817 shares in the last quarter. Finally, Pura Vida Investments LLC boosted its position in Beta Bionics by 11,150.0% during the 3rd quarter. Pura Vida Investments LLC now owns 281,250 shares of the company's stock worth $5,588,000 after acquiring an additional 278,750 shares during the period.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on BBNX. Bank of America boosted their price target on Beta Bionics from $30.00 to $33.00 and gave the company a "buy" rating in a report on Monday. Piper Sandler restated an "overweight" rating and issued a $32.00 price target (up from $26.00) on shares of Beta Bionics in a research report on Wednesday, October 29th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Beta Bionics in a research note on Monday, December 29th. Lake Street Capital restated a "buy" rating and issued a $35.00 target price on shares of Beta Bionics in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group upped their target price on Beta Bionics from $26.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.70.
Read Our Latest Analysis on BBNX
About Beta Bionics
(
Get Free Report)
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
